Several CSF biomarkers have been used for clinical diagnosis of AD, such as decreased levels of Aβ1‐42 identified on a positron emission tomography (PET) scan, increased levels of total tau on MRI, high levels of tau phosphorylated at threonine 181 (p‐tau181) on MRI.5, 6, 7. Here, MAPT is linked to Alzheimer disease.